RECANOVA Registry for Medtronic Neurovascular Products in Acute Ischemic Stroke
This study, called the RECANOVA Registry, is looking at how well Medtronic Neurovascular products work and how safe they are when used to treat acute ischemic stroke (a type of stroke caused by a blood clot). It's an observational study, meaning researchers will collect information from patients who are already being treated with these devices. The study aims to understand the safety, performance, and effectiveness of these devices from the time of the procedure up to 90 days later. You may be able to join if you are 18 or older and are being treated with a commercially available Medtronic Neurovascular device for an acute ischemic stroke. The current recruitment status is unclear.
- Study design
- This is an observational study that plans to enroll about 1500 participants. It is a single-arm study, meaning all participants receive the same intervention.
- What's involved
- You would participate in the index stroke procedure and follow-up visits up to 90 days after the procedure.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 90 days after the procedure.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
At a glance
Conditions
NCT07599904
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Buffalo General Medical Center
Buffalo, New Yorkstudy coordinator listed
Recruiting
McLaren Flint Hospital
Flint, Michiganstudy coordinator listed
Recruiting
University of Texas Health Science Center at Houston
Houston, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Evaluate device safetyFrom Day 0 to 90 days post-procedure
Incidence of Safety Events of Interest through 90-day follow-up
- Evaluate device performanceDay 0 - end of index stroke procedure
Reperfusion defined as eTICI ≥2b50; ≥2b67; ≥2c; =3 at end of procedure.
- Evaluate device effectivenessFrom Day 0 to 90 days post-procedure
Functional independence as measured by modified Rankin Scale (mRS) score ≤ 2 at 90-day follow up (mRS scores range from 0 \[no symptoms\] to 6 \[death\]).